H

ello, everyone, and how are you today? We are just fine, thank you, despite the mounds of snow and frigid temperatures enveloping the otherwise sunny Pharmalot campus, where the short person is sleeping in. Keeping warm is a must right now, though, so we are doing so with the help of several cups of stimulation. No surprise, right? Our flavor, once again, is Cinnamon Dolce, for those keeping track. Please feel free to join us. As always, here are a few items of interest. Perhaps, these will also warm up you up. Have a cheery day and do keep in touch with us …

The new GlaxoSmithKline chief executive, Emma Walmsley, will be paid 25 percent less than her predecessor, Andrew Witty, the Guardian reports. The approximately $10.7 million annual pay deal is lower than the $14 million given Witty because she was less experienced than her predecessor, who spent eight years as chief executive, and follows protests from some investors who asked the drug maker to restrain executive pay.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.